Spasmodic Dysphonia in Multiple Sclerosis Treatment With Botulin Toxin A: A Pilot Study.

Area of Science:

• Neurology
• Otolaryngology
• Speech Pathology

Background:

• Multiple sclerosis (MS) can lead to neurological voice disorders like spasmodic dysphonia (SD).
• Current treatment options for SD in MS patients are limited, necessitating further research into effective therapies.

Observation:

• A pilot study investigated the efficacy and safety of botulinum toxin A injections for treating SD in three relapsing-remitting MS patients.
• Long-term observation was conducted to assess treatment durability and potential adverse effects.

Findings:

• Botulinum toxin A treatment resulted in significant improvements in voice quality and laryngostroboscopy findings.
• No patients experienced dysphagia or other adverse events, indicating a favorable safety profile.
• The therapeutic effects of botulinum toxin A were sustained for 6-8 months post-treatment.

Implications:

• Botulinum toxin A presents a safe and effective therapeutic option for managing spasmodic dysphonia in individuals with multiple sclerosis.
• These findings support the potential of botulinum toxin A as a valuable intervention for improving vocal function in this patient population.
• Larger-scale clinical trials are warranted to validate these preliminary results and establish definitive treatment guidelines.